¡ á µm k · k v ® ñ ¨ ª ¸ · v Üpresentation outline 3 g9gygmgfgx 2fþ /(Ô w g9gygmgfgx1...
Post on 24-Jul-2020
1 Views
Preview:
TRANSCRIPT
Points to consider for environmental risk assessment of the use of living modified organisms; PMDA perspectives on type 1 use approval and type 2 use confirmation under “Cartagena Law”
Special Symposium II: Biosafety Regulations in Gene Therapy (J)
2
Presentation Outline
3
GILSP GILSP
4
5
WHO Certification Scheme on the Quality of Pharmaceutical Moving in International Commerce
6
••
7
••
8
CHO
9
10
•
•
•11
12
13
14
•
•
•
•
•
•
15
30
16
17
••
•
••
•
•18
•••
••••••
19
••••
••
••••• J-BCH
http://www.biodic.go.jp/bch/20
21
22
PMDA Consultation…
Conclusion
23
http://www.pmda.go.jp/review-services/drug-reviews/cartagena-act/0003.html
top related